Background:
Elevated lipoprotein(a) [Lp(a)] is a heritable, independent risk factor for atherosclerotic cardiovascular disease, and it is not meaningfully reduced by statins or ezetimibe. Whether elevated Lp(a) translates into measurable residual cardiovascular and limb ischemic risk in patients who have achieved an...
Maryam Mojarrad Sani, A. Nouri, Ashkan Abdollahi et al.· Circulation· 0 citations
Dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 receptor inhibitor (P2Y12i), remains the cornerstone of secondary prevention of thrombotic complications after acute coronary syndrome (ACS). However, the optimal P2Y12i to use as part of DAPT in patients with ACS remains uncertain.
We aimed...
M. Joseph, Mrinal Murali Krishna, X. Jacquemyn et al.· European Heart Journal· 0 citations
LAAO demonstrated efficacy comparable to DOAC therapy in reducing the risk of MACCE, NACE, and ischemic events, while significantly reducing the risk of non-procedure-related bleeding.
Chidubem Ezenna, Khalid Sawalha, Sammudeen Ibrahim et al.· Pacing and clinical electrop...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.